三阴性乳腺癌治疗进展

Progression of triple-negative breast cancer treatment

三阴性乳腺癌(TNBC)是ER、PR、HER2受体均阴性的乳腺癌,是具有独特的生物学及临床特征的乳腺癌亚型,与基底细胞样乳腺癌有较高的一致性。众所周知ER、PR、HER2的表达是目前临床乳腺癌治疗的靶点,但TNBC患者因为缺少这些靶点,不能从内分泌治疗及靶向治疗中获益,导致了其预后差、复发转移率高、死亡率高,也因此成为近几年乳腺癌研究和关注的焦点。本文旨在对TNBC治疗相关的国内外研究现状做一综述。

Triple - negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptor（ER/PR） and HER2 protein. And there is a great deal of overlap between triple - negative and basal - like breast cancer. We know that ER, PR and HER2 are the recently targets for target therapy, but triple - negative breast cancer lack of these targets, so that they could not obtain benefits from endocrine therapy and target therapy and also leads to the characters of poor prognosis, high distant metastases and death rate. So it became the focus of study. This review aim at summarizing the research status and providing treatment information.